CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay","$":{"href":"/medtech/eckman-coulter-grows-alzheimers-dx-portfolio-ce-mark-new-assay","hreflang":"en"}}]}

RegulatoryapprovedAccess p-Tau217 assayPositive
AI Analysis

Summary

Beckman Coulter obtained CE mark approval in Europe for its Access p-Tau217 assay, expanding its Alzheimer's disease diagnostic portfolio.

Outcome Details

CE mark approval in Europe

Importance:5/10
Sentiment:
0.60
diagnosticsAlzheimer's diseaseCE markEuropeportfolio expansion

Read the original article

Published by FierceBiotech on July 7, 2026 7:57 AM

Read Original